Polarean announces new deal with Virginia hospital.


Medical imaging tech group Polarean Imaging has announced a new supply agreement with the University of Virginia Health, giving shares of the AIM-listed outfit a bump on Monday.

  • Polarean Imaging
  • 29 September 2025 10:02:30
Polarean Imaging

Source: Sharecast

The agreement covers the implementation of full clinical Xenon MRI capabilities for UVA Health, an integrated health system in Virginia with an academic medical centre that includes a Comprehensive Cancer Center and peadiatric hospital UVA Health Children's.

Having upgraded its two research-grade hyperpolarisers to clinical-grade systems in 2024 provided by Polarean, UVA Health now needs additional equipment to enable clinical Xenon MRI scans in their clinical imaging area.

"We are delighted to support UVA Health as they prepare to launch their first clinical Xenon MRI scan, anticipated to occur later this year. Their deep and sustained commitment to advancing pulmonary imaging - from early research breakthroughs to today's clinical transition - perfectly aligns with Polarean's mission to provide critical imaging solutions for chronic lung disease," said Polarean's chief executive Christopher von Jako.

"UVA Health's decades-long leadership in Xenon MRI has been instrumental in shaping the field, and we look forward to continuing our partnership to improve lung health for patients everywhere."

Shares were 4% higher at 0.52p by 0916 BST.


N/A

ISIN: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.